Invicro

New Haven, Connecticut 06510

0 studies enrolling now · 20 studies all time

What they study most

Alpha-Synucleinopathy, Alzheimer Disease, Alzheimer's Disease, Dementia With Lewy Bodies, Healthy, Healthy Male Volunteers, Healthy Volunteer, Healthy Volunteers, Healthy Volunteers (HV), Multisystem Atrophy, Neoplasms, Parkinson Disease

Studies at this site

• A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer — Recruiting now
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants — Completed
• A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants — Completed
• Plasma P-tau2017 and Quantitative Amyloid PET Imaging — Completed
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein — Completed
• Evaluation of [18F]APN-1607 as a PET Biomarker — Completed
• Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain — Completed
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early
• Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444 — Completed
• Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein — Completed
• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss — Completed
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PET — Completed
• Assessment of [18F]MNI-1054 as a Marker for LSD1 — Completed
• Assessment of the Biodistribution and Safety of [18F]MNI-1054 — Completed
• D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 — Completed
• Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects — Completed